Scholarlink

<p>The Fas-FasL system is a central regulator of apoptosis, immune homeostasis, and tissue equilibrium. This pathway is mediated by Fas (CD95/APO-1) and its ligand FasL (CD95L/APO-1&#xa0;L), which upon interaction assemble the death-inducing signaling complex (DISC) and initiate downstream signaling cascades that can result in apoptosis or non-apoptotic immune responses. Dysregulation of this pathway contributes to diverse pathologies. Impaired expression or signaling of Fas or FasL disrupts the elimination of autoreactive lymphocytes, undermining self-tolerance and promoting autoimmune disease. Fas-FasL interactions also play a critical role in balancing effector and regulatory T-cell responses. These insights have driven interest in combination therapies that modulate Fas signaling alongside immunosuppressive agents to enhance efficacy while minimizing toxicity. Future therapeutic strategies will require selective targeting of disease-specific Fas/FasL-expressing cells to avoid damage to healthy tissues. Advances in targeted delivery platforms, including nanoparticles and antibody-based carriers, may improve this specificity. Continued investigation into how Fas-FasL integrates with other immune checkpoints, such as PD-1/PD-L1 and CTLA-4, will be essential for designing synergistic immunomodulatory approaches. Collectively, this review highlights the multifaceted roles of the Fas-FasL pathway and its emerging therapeutic potential in cancer, autoimmune disorders, and allograft tolerance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Fas-FasL system: from apoptosis regulator to therapeutic target in autoimmunity, cancer, and transplantation

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Mohamed Gadelkarim,
  • Ahmed Elsayed,
  • Abubakar Nazir,
  • Yousif Elsayed,
  • Ayham Habashneh,
  • Omer Iqbal,
  • Badi Rawashdeh

摘要

The Fas-FasL system is a central regulator of apoptosis, immune homeostasis, and tissue equilibrium. This pathway is mediated by Fas (CD95/APO-1) and its ligand FasL (CD95L/APO-1 L), which upon interaction assemble the death-inducing signaling complex (DISC) and initiate downstream signaling cascades that can result in apoptosis or non-apoptotic immune responses. Dysregulation of this pathway contributes to diverse pathologies. Impaired expression or signaling of Fas or FasL disrupts the elimination of autoreactive lymphocytes, undermining self-tolerance and promoting autoimmune disease. Fas-FasL interactions also play a critical role in balancing effector and regulatory T-cell responses. These insights have driven interest in combination therapies that modulate Fas signaling alongside immunosuppressive agents to enhance efficacy while minimizing toxicity. Future therapeutic strategies will require selective targeting of disease-specific Fas/FasL-expressing cells to avoid damage to healthy tissues. Advances in targeted delivery platforms, including nanoparticles and antibody-based carriers, may improve this specificity. Continued investigation into how Fas-FasL integrates with other immune checkpoints, such as PD-1/PD-L1 and CTLA-4, will be essential for designing synergistic immunomodulatory approaches. Collectively, this review highlights the multifaceted roles of the Fas-FasL pathway and its emerging therapeutic potential in cancer, autoimmune disorders, and allograft tolerance.